Zacks Investment Research downgraded Tobira Therapeutics Inc (NASDAQ:TBRA) to Sell in a report released today.
- Updated: October 14, 2016
Yesterday Tobira Therapeutics Inc (NASDAQ:TBRA) traded -0.30% lower at $40.21. Tobira Therapeutics Inc’s 50-day moving average is $23.82 and its two hundred day average is $12.32. With the last stock price close up 226.40% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 88,179 shares of TBRA traded hands, down from an average trading volume of 632,146
Zacks Investment Research has downgraded Tobira Therapeutics Inc (NASDAQ:TBRA) to Sell in a report released on Saturday October 15, 2016.
Recent Performance Chart
Tobira Therapeutics Inc has 52 week low of $3.76 and a 52 week high of $41.39 and has a market cap of $0.
In addition to Zacks Investment Research reporting its target price, a total of 3 brokers have issued a report on the stock. The consensus target price is $20.33 with 1 broker rating the stock a strong buy, two brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and lastly zero brokerages rating the company a sell.
General Company Details For Tobira Therapeutics Inc (NASDAQ:TBRA)
Tobira Therapeutics, Inc., formerly Regado Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company's lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV. The Company's CVC product candidate is an oral, once-daily immunomodulator that blocks the chemokine receptors, CCR2 and CCR5, which are involved in the inflammatory and fibrogenic pathways in NASH and PSC that cause liver damage, and can lead to cirrhosis, liver cancer or liver failure. It is conducting a global Phase IIb study evaluating CVC in NASH patients with liver fibrosis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.